BiotechTube
Vitrolife AB

Vitrolife AB

VITR.STPre-clinical
1,500-2,000 employeesvitrolife.com

Vitrolife is a global leader in reproductive medicine, dedicated to developing innovative products and services that help IVF clinics achieve higher success rates and improve patient outcomes. The company's integrated portfolio includes media for embryo culture, vitrification solutions for cryopreservation, time-lapse incubators, and clinic management software. With a strong presence in over 110 countries, Vitrolife combines scientific expertise with practical solutions to address the growing global demand for fertility treatments.

Market Cap
$1.3B
-46.6% period
Pipeline
1
drug candidates
Patents
1
granted
Publications
20
indexed

VITR.ST · Stock Price

USD 89.0077.70 (-46.61%)

Historical price data

AI Company Overview

Vitrolife is a global leader in reproductive medicine, dedicated to developing innovative products and services that help IVF clinics achieve higher success rates and improve patient outcomes. The company's integrated portfolio includes media for embryo culture, vitrification solutions for cryopreservation, time-lapse incubators, and clinic management software. With a strong presence in over 110 countries, Vitrolife combines scientific expertise with practical solutions to address the growing global demand for fertility treatments.

Reproductive MedicineFertilityGenetics

Technology Platform

Integrated platform for reproductive medicine including embryo culture media, vitrification solutions, time-lapse incubation systems, and preimplantation genetic testing services.

Pipeline

1
1 drug in pipeline
DrugIndicationStageWatch
Acetyl-L-carnitine (ALC), N-acetyl-L-cysteine (NAC) and α-li...Culture MediaPre-clinical

Funding History

1
IPOUndisclosedJun 15, 2001

Opportunities

Vitrolife has significant growth opportunities through geographic expansion into emerging markets, increased adoption of genetic testing in reproductive medicine, and development of AI-enhanced embryo selection tools.
The growing global demand for fertility services, coupled with improving reimbursement policies, creates a favorable market environment for continued expansion.

Risk Factors

Key risks include regulatory changes affecting product approvals, pricing pressure from healthcare systems, integration challenges following the Igenomix acquisition, and technological disruption from competitors.
The company also faces ethical and social controversies surrounding IVF and genetic testing that could impact demand.

Competitive Landscape

Vitrolife competes with CooperSurgical, Cook Medical, and Irvine Scientific in culture media; Esco Medical in time-lapse incubation; and Natera and CooperGenomics in genetic testing. The company differentiates through its integrated portfolio approach, strong scientific reputation, and global distribution network, offering clinics a comprehensive solution from embryo culture to genetic analysis.